Multi-target drugs: The trend of drug research and development

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Lu, Jin Jian ^a   Pan, Wei ^a   Hu, Yuan Jia ^a   Wang, Yi Tao ^a  

^a University of Macau   (Macao)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ADRENERGIC RECEPTOR; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; AZACITIDINE; BORTEZOMIB; CENTRAL NERVOUS SYSTEM AGENTS; DASATINIB; DNA; DOPAMINE RECEPTOR; ENFUVIRTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; HISTAMINE RECEPTOR; HISTONE DEACETYLASE; IMATINIB; LAPATINIB; NELARABINE; OXALIPLATIN; PROTEASOME; PROTEIN TYROSINE KINASE; RIFAXIMIN; SEROTONIN RECEPTOR; SITAGLIPTIN; SORAFENIB; SUNITINIB; VORINOSTAT;

ARTICLE; COMMERCIAL PHENOMENA; DATA ANALYSIS; DRUG APPROVAL; DRUG MARKETING; DRUG RESEARCH; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; UNITED STATES;

EID: 84863085673     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040262     Document Type: Article

References (46)

1. Csermely P, Agoston V, Pongor S, (2005) The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 26: 178-182.
2. Puls LN, Eadens M, Messersmith W, (2011) Current status of SRC inhibitors in solid tumor malignancies. Oncologist 16: 566-578.
3. Stella GM, Luisetti M, Inghilleri S, Cemmi F, Scabini R, et al. (2012) Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies. Respir Med 106: 173-183.
4. Boran AD, Iyengar R, (2010) Systems approaches to polypharmacology and drug discovery. Curr Opin Drug Discov Devel 13: 297-309.
5. Petrelli A, Giordano S, (2008) From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem 15: 422-432.
6. Yildirim MA, Goh KI, Cusick ME, Barabasi AL, Vidal M, (2007) Drug-target network. Nat Biotechnol 25: 1119-1126.
7. Zhang S, Hu Y, Yin H, Wang Y, (2011) Drug targets and economic value: an empirical study based on new drugs marketed in US during recent ten years. Sci Tec Man Res 31: 172-175.
8. Ciuffreda L, Di Sanza C, Incani UC, Milella M, (2010) The mTOR pathway: a new target in cancer therapy. Curr Cancer Drug Targets 10: 484-495.
9. Courtney KD, Corcoran RB, Engelman JA, (2010) The PI3K pathway as drug target in human cancer. J Clin Oncol 28: 1075-1083.
10. Canta A, Chiorazzi A, Cavaletti G, (2009) Tubulin: a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system. Curr Med Chem 16: 1315-1324.
11. Al-Janadi A, Chandana SR, Conley BA, (2008) Histone deacetylation: an attractive target for cancer therapy? Drugs R D 9: 369-383.
12. Moreira L, Castells A, (2011) Cyclooxygenase as a target for colorectal cancer chemoprevention. Curr Drug Targets 12: 1888-1894.
13. Frankland-Searby S, Bhaumik SR, (2012) The 26S proteasome complex: an attractive target for cancer therapy. Biochim Biophys Acta 1825: 64-76.
14. Zhou Y, Chen Y, Tong L, Xie H, Wen W, et al. (2012) AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and antitumor activity via targeting VEGFR, FGFR, and PDGFR. J Cell Mol Med doi:10.1111/j.1582-4934.2012.01541.x.
15. Antoniu SA, Kolb MR, (2010) Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis. IDrugs 13: 332-345.
16. Golubovskaya VM, (2010) Focal adhesion kinase as a cancer therapy target. Anticancer Agents Med Chem 10: 735-741.
17. Glisson BS, Ross WE, (1987) DNA topoisomerase II: a primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy. Pharmacol Ther 32: 89-106.
18. Motoshima H, Goldstein BJ, Igata M, Araki E, (2006) AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 574: 63-71.
19. Bolognesi ML, Cavalli A, Valgimigli L, Bartolini M, Rosini M, et al. (2007) Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease. J Med Chem 50: 6446-6449.
20. Zhu Y, Xiao K, Ma L, Xiong B, Fu Y, et al. (2009) Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase. Bioorg Med Chem 17: 1600-1613.
21. Gong CX, Iqbal K, (2008) Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem 15: 2321-2328.
22. Ziani-Cherif C, Mostefa-Kara B, Brixi-Gormat FZ, (2006) Gamma-secretase as a pharmacological target in Alzheimer disease research: when, why and how? Curr Pharm Des 12: 4313-4335.
23. Gokhan-Kelekci N, Yabanoglu S, Kupeli E, Salgin U, Ozgen O, et al. (2007) A new therapeutic approach in Alzheimer disease: some novel pyrazole derivatives as dual MAO-B inhibitors and antiinflammatory analgesics. Bioorg Med Chem 15: 5775-5786.
24. Chang C, Dong R, Miyazaki A, Sakashita N, Zhang Y, et al. (2006) Human acyl-CoA:cholesterol acyltransferase (ACAT) and its potential as a target for pharmaceutical intervention against atherosclerosis. Acta Biochim Biophys Sin (Shanghai) 38: 151-156.
25. Navarra T, Del Turco S, Berti S, Basta G, (2010) The lectin-like oxidized low-density lipoprotein receptor-1 and its soluble form: cardiovascular implications. J Atheroscler Thromb 17: 317-331.
26. Soskic SS, Dobutovic BD, Sudar EM, Obradovic MM, Nikolic DM, et al. (2011) Peroxisome proliferator-activated receptors and atherosclerosis. Angiology 62: 523-534.
27. Duivenvoorden R, Fayad ZA, (2011) Utility of atherosclerosis imaging in the evaluation of high-density lipoprotein-raising therapies. Curr Atheroscler Rep 13: 277-284.
28. Frantz S, (2005) Drug discovery: playing dirty. Nature 437: 942-943.
29. Ament Z, Masoodi M, Griffin JL, (2012) Applications of metabolomics for understanding the action of peroxisome proliferator-activated receptors (PPARs) in diabetes, obesity and cancer. Genome Med 4: 32.
30. Zheng H, Amit T, Bar-Am O, Fridkin M, Youdim MB, et al. (2012) From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease. J Alzheimers Dis 30: 1-16.
31. Schapira AH, (2011) Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects. CNS Drugs 25: 1061-1071.
32. Quintas-Cardama A, Cortes J, (2008) Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases. Future Oncol 4: 611-621.
33. Wei D, Jiang X, Zhou L, Chen J, Chen Z, et al. (2008) Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J Med Chem 51: 7882-7888.
34. Harvey AL, (2008) Natural products in drug discovery. Drug Discov Today 13: 894-901.
35. Guo ZR, (2012) Modification of natural products for drug discovery. Yao Xue Xue Bao 47: 144-157.
36. Das T, Sa G, Saha B, Das K, (2010) Multifocal signal modulation therapy of cancer: ancient weapon, modern targets. Mol Cell Biochem 336: 85-95.
37. Tan W, Lu J, Huang M, Li Y, Chen M, et al. (2011) Anti-cancer natural products isolated from chinese medicinal herbs. Chin Med 6: 27.
38. Gupta SC, Kim JH, Prasad S, Aggarwal BB, (2010) Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 29: 405-434.
39. Gupta SC, Prasad S, Kim JH, Patchva S, Webb LJ, et al. (2011) Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep 28: 1937-1955.
40. Gupta SC, Patchva S, Koh W, Aggarwal BB, (2012) Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol 39: 283-299.
41. Sun Y, Xun K, Wang Y, Chen X, (2009) A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs. Anticancer Drugs 20: 757-769.
42. Srinivas NR, (2010) Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives. Xenobiotica 40: 357-367.
43. Patel L, Grossberg GT, (2011) Combination therapy for Alzheimer's disease. Drugs Aging 28: 539-546.
44. Zhang H, Jia H, Liu J, Ao N, Yan B, et al. (2010) Combined R-alpha-lipoic acid and acetyl-L-carnitine exerts efficient preventative effects in a cellular model of Parkinson's disease. J Cell Mol Med 14: 215-225.
45. Kim JH, Park SH, Bae SS, Hong KW, Kim YD, et al. (2011) Combinatorial effect of probucol and cilostazol in focal ischemic mice with hypercholesterolemia. J Pharmacol Exp Ther 338: 451-457.
46. S KS, Gupta A, Bhagyashree K, Saxena R, Arora N, et al. (2012) Targeting strategies for human immunodeficiency virus: a combinatorial approach. Mini Rev Med Chem 12: 236-254.